---
title: "Why Is Armata Pharma Stock Gaining Monday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293240768.md"
description: "Armata Pharmaceuticals (ARMP) stock rose over 10% following announcements of significant progress for its lead candidate AP-SA02. The company submitted its Phase 3 protocol to the FDA and completed manufacturing runs at its Los Angeles facility, preparing for a pivotal trial in late 2026. Additionally, Armata secured $28.7 million in cumulative Department of Defense funding and promoted David House to CFO."
datetime: "2026-07-20T16:45:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293240768.md)
  - [en](https://longbridge.com/en/news/293240768.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293240768.md)
generator: "portal-rs"
---

# Why Is Armata Pharma Stock Gaining Monday?

**Armata Pharmaceuticals Inc.** (NYSE:ARMP) stock is trading higher on Monday after the company announced significant clinical, regulatory, manufacturing, and operational progress supporting the advancement of its lead therapeutic candidate, AP-SA02.

The late clinical-stage biotechnology business is moving the intravenously administered Staphylococcus aureus multi-phage product toward a pivotal Phase 3 superiority study set to begin in the second half of 2026.

The upcoming trial is designed to support a future Biologics License Application for the treatment of complicated bacteremia caused by methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains.

 **Read Also: Why UnitedHealth Can't Stop Saying One Word: 'Restless'** 

## Regulatory Alignment And Operational Readiness

Armata said it submitted the complete Phase 3 protocol to the U.S. Food and Drug Administration. The filing also included responses to all feedback from the agency’s End-of-Phase 2 meeting.

These submissions resolved inquiries across clinical, regulatory, and chemistry, manufacturing, and controls parameters.

Operationally, the company concluded four engineering runs for the candidate at its in-house cGMP facility located in Los Angeles, California.

Manufacturing clinical trial material at this facility serves as the next planned step to prepare for late-stage clinical evaluation.

## Clinical Background And Government Backing

AP-SA02 is being developed as an adjunct treatment combined with best available antibiotic therapy.

The multi-phage cocktail has earned Qualified Infectious Disease Product and Fast Track designations from regulatory authorities.

Armata previously reported positive safety, tolerability and efficacy data from its Phase 1b/2a diSArm study. The company presented those results during a late-breaking oral session at IDWeek 2025.

To assist with trial readiness, the company secured a $2.5 million continuation award from the U.S. Department of Defense in June.

The milestone brings cumulative funding under the award to $28.7 million. Management continues active dialogue with defense officials regarding potential expanded support for trial execution while simultaneously assessing additional external funding pathways.

## Executive Leadership Update

Armata also promoted **David House** to chief financial officer. He previously served as senior vice president of finance and principal financial officer since August 2024.

**ARMP Stock Price Activity**: Armata Pharmaceuticals shares were up 10.27% at $4.97 at the time of publication on Monday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: AMD Rises After Microsoft's Helios Win: Is Nvidia Finally Facing Real Competition?**

### Related Stocks

- [ARMP.US](https://longbridge.com/en/quote/ARMP.US.md)
- [UNH.US](https://longbridge.com/en/quote/UNH.US.md)
- [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md)
- [AMD.US](https://longbridge.com/en/quote/AMD.US.md)
- [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md)
- [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md)

## Related News & Research

- [Armata Advances AP-SA02 Toward Phase 3 Trial Launch](https://longbridge.com/en/news/293209036.md)
- [Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment](https://longbridge.com/en/news/293234406.md)
- [Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program](https://longbridge.com/en/news/290552106.md)
- [Armata swings to FY26 Q2 net income of $74.14 million; operating loss widens to $10.31 million](https://longbridge.com/en/news/295703083.md)
- [07:00 ETArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"](https://longbridge.com/en/news/285060911.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**